Mohammad Vaziri’s Post

For most patients with ER+, HER2- #MetastaticBreastCancer (MBC), endocrine therapy is the therapeutic backbone throughout their treatment journey and used frequently in regimen combinations. Endocrine therapies target the estrogen receptor pathway, either by blocking receptor binding using an antagonist or by depriving the tumor of estrogen. Click here to discover endocrine therapies that target the estrogen receptor pathway in MBC: https://e.lilly/3Sukz8G #BreastCancer #BCSM #MBC

Tevimbra, a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor, was approved on March 13th. The overall grade is C with good representation of elderly and Asians (both B grades). Of note the highest enrolling countries were China and Japan. The representation of Black participants was poor (F Grade) with NO Black participants receiving Tevimbra. Note that ESCC is increased in Blacks.

"Singapore has recently seen a biotech resurgence in the form of cell therapy and cell science-related start-ups." "This resurgence is undoubtedly inspired in large part by recent clinical successes using T-cell immunotherapy and associated technologies, particularly in the treatment of cancers and autoimmune diseases." -> https://shorturl.at/1Ho3P #CarTcells #cartcelltherapy #cancertherapy #biotechstocks #biotech #undervalued #immunotherapy #nasdaq #nasdaqstocks #preclinical #gdtc #investing

Research Article Complement Proteins L-Ficolin and M-Ficolin Are Increased in Patients With Axial Spondyloarthritis and Decrease After Tumor Necrosis Factor Inhibitor Treatment 📰 https://lnkd.in/gG-rr6xa #axialspondyloarthritis #lectinpathwayproteins

📈Presented at ASH: promising outcomes of CAR-T therapy AT101, in a Phase I clinical trial A new trial of the University of Pennsylvania developed AT101 therapy demonstrated a 100% complete response rate in B cell non-Hodgkin’s lymphoma patients at higher doses. Lead researcher Marco Ruella, MD, emphasises the impact of CAR design on T-cell function, suggesting a potential shift in treatment efficacy. The drug is well tolerated with manageable side effects, prompting the progression to Phase II trials. This development holds promising implications for reshaping CAR-T therapy and expanding treatment options for patients. 🔍 Read more about the study: https://lnkd.in/g55KF69E #manufacturingbrighterfutures #celltherapy #genetherapy #biotechnology #digitalhealth

Is cell-avidity tuning the solution for safe CAR-T therapy for solid tumors? 👀 The shortage of tumor-specific antigens is one of the major challenges in CAR-T therapy for solid tumors. Solid tumors are heterogenous in antigen expression which makes the identification of suitable target antigens essential in CAR-T therapy. 🔎 LUMICKS’s technology, the z-Movi Cell Avidity Analyser allows the assessment of cell binding strength and the tailoring of safer CAR-T therapies. 🖥️ Find out more in our article! ⬇️ https://lnkd.in/dxpyqK-q #CAR-Ttherapy #solidtumors #cellaviditytuning #cancerresearch #Immunotherapy #biotechinnovation #medicaltechnology

【The NORE1A/RASSF5 Tumor Suppressor Forms a Complex with GSK-3β to Regulate β-Catenin】 Full article: https://lnkd.in/gWAege-5 (Authored by M. Lee Schmidt, et al., from University of Louisville (USA), etc.) NORE1A (Novel Ras Effector 1 or #RASSF5) is a member of the RASSF family of tumor suppressors. In human tumors, NORE1A expression is frequently down-regulated as a result of promoter hyper-methylation or Calpain-mediated proteolysis. This study identifies a new signaling partner for #NORE1A, GSK-3β, and shows that NORE1A scaffolds the kinase and the ubiquitin ligase complex that is required to promote #β_catenin degradation and modulation of the Wnt pathway. Official link for submission:https://lnkd.in/gf-cXBTN

https://lnkd.in/gsvsv4pC TRK inhibitor with good kinase selectivity that also blocked cellular TRK signaling, thereby inhibiting TRK-dependent cell viability with acceptable pharmacokinetic properties, 37.8% oral bioavailability in mice and strong in vivo tumor growth inhibition.

Cell therapy has the promise to cure multiple forms of cancer in the coming decades. It makes use of genetically modified immune cells that recognise, bind and kill the tumour cells. A huge challenge in developing these therapies is ensuring that the product only attacks the tumour cells and not the healthy cells of the patient. This is intrinsically hard for cancer cells since these were already able to evade the immune system and look pretty similar to healthy cells from the outside. To this extend the immune product needs to be “tuned” to only bind and recognise to tumor cells and not bind to healthy cells. This happens on the timescale of minutes and is exactly this what we can directly quantify with the LUMICKS Cell Avidity product. Exciting to see that the renowned institute Dana Farber (Yufei (Sophie) Wang) was able to avidity tune their product to improve the safety of their cell therapy. At LUMICKS we are humbled to be able to support such research that will impact human life. 

✨ Published in #Cell: The article developed a highly multiplexed mass cytometry platform to measure post-translational modification (PTM) signaling, #DNA damage, cell-cycle activity, and #apoptosis in >2,500 #colorectal #cancer (CRC) PDOs and cancer-associated #fibroblasts (CAFs) in response to clinical therapies at single-cell resolution. 🎈 To compare patient- and #microenvironment-specific drug responses in thousands of single-cell datasets, we developed “Trellis”—a highly scalable, tree-based treatment effect analysis method. Trellis single-cell screening revealed that on-target cell-cycle blockage and DNA-damage drug effects are common, even in chemore fractory PDOs. 📣 Related Product Recommendation: #Cetuximab Cetuximab (C225) is a human IgG1 monoclonal #antibody that inhibits epidermal growth factor receptor (#EGFR), with a #Kd of 0.201 nM for EGFR by #SPR. Cetuximab has potent #antitumor activity. https://lnkd.in/gu3Wu7as 👉 For more detailed information: https://lnkd.in/ghgJyGsH